Dr. Luis Pineiro, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Puerto Rico School of Medicine (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 164
Licensed in Texas since 1991, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: University of Puerto Rico School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license J0632 (first issued 1991; active) -
Medical Oncology Physician
TX license J0632 (first issued 1991; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor University Medical Center Dallas, TX
- Baylor Scott & White Heart & Vascular Hospital - Dallas Dallas, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 164
- Services billed
- 29,134
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 3,990 | 27 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 288 | 40 |
| Blood test, comprehensive group of blood chemicals | 273 | 62 |
| Lactate dehydrogenase (enzyme) level | 244 | 60 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 239 | 34 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 201 | 57 |
| Magnesium level | 177 | 46 |
| Insertion of needle into vein for collection of blood sample | 172 | 53 |
| Established patient office or other outpatient visit, 30-39 minutes | 157 | 53 |
| Injection of additional new drug or substance into vein | 81 | 32 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Dallas, TX | 84 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Dallas, TX | 81 |
| Acyclovir Other prescribers in Dallas, TX | 77 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Dallas, TX | 68 |
| Alprazolam Other prescribers in Dallas, TX | 67 |
| Jakafi (ruxolitinib phosphate) | 51 |
| Rezurock (belumosudil mesylate) | 45 |
| Pantoprazole Sodium Other prescribers in Dallas, TX | 36 |
| Dexamethasone Other prescribers in Dallas, TX | 32 |
| Oxycodone Hcl Other prescribers in Dallas, TX | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 34 payments worth $864 in total to this clinician.
| Incyte Corporation | $89.62 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $79.82 |
| GlaxoSmithKline, LLC. | $69.67 |
| Alexion Pharmaceuticals, Inc. | $63.68 |
| Janssen Biotech, Inc. | $61.04 |
| Syndax Pharmaceuticals, Inc. | $51.54 |
| Daiichi Sankyo Inc. | $51.02 |
| Sobi, Inc | $49.86 |
| Food and Beverage | $864 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $22,988 in research payments for these studies, mostly to the institutions running them.
- A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. · Terminated · NCT04161885 - M19-063 - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.